Abstract: The present invention relates to hyper harmonized hydroxyl-modified fullerenes, hydroxyl-modified fullerenes in a suitable carrier, and hydroxyl-modified fullerene formulations including a suitable carrier with optional additives. These compositions of matter and formulations have numerous applications including, for example, the cosmetic industry, dietary supplements, food industry, plants and healthcare fields.

Abstract: Disclosed herein are polymeric implants and controlled release drug delivery systems to provide high drug loading and long-acting drug release. Provided herein are methods for making the same. Methods of administering pharmacologically active agents via the disclosed polymeric implants and controlled release drug delivery systems are also provided.

Abstract: The present application relates to an aqueous pharmaceutical composition for use as a paediatric medicament in the treatment or prevention of vitamin A deficiency or a vitamin A deficiency-associated disease.

Abstract: The invention belongs to the technical field of agricultural chemicals, and in particular relates to a pyridazinol compound represented by the Formula I, a derivative, preparation method, herbicidal composition and use thereof.

Abstract: An aqueous formulation including a three-dimensional helical cage structure of polygonal water molecules, wherein the polygonal water molecules include two or more adjacent water molecules connected by hydrogen bridges, the helical cage structure has a central hollow lumen, and when viewed from a top, the helical cage structure has a hexagonal shape. The aqueous formulation also includes molecular hydrogen and at least one additive located within the central hollow lumen of the helical structure.

Abstract: The present invention provides, in part, di-thioester cationic lipid compounds or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

Abstract: Disclosed herein are compositions comprising silver nanoparticles with uniform particles and a narrow particle size distribution. Also disclosed herein are processes for preparing and purifying the dispersions of silver nanoparticles.

Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein R1, R2, R3, R4, R5, R6, m and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Abstract: A lyophilized powder of latamoxef sodium for injection and a lyophilization method thereof are provided. The lyophilized powder of latamoxef sodium for injection includes the following raw materials by weight: 20˜40 parts of latamoxef sodium, 8˜15 parts of lyophilized adjuvant, 6˜18 parts of excipient and 30˜55 parts of water; by optimizing a raw material process thereof, the present disclosure prepares lyophilized adjuvant and performs twice drying, so that the raw material has stable quality, less impurities, high purity, less adverse reactions and high efficacy; at the same time, the preparation process is innovated and improved to reduce a preparation temperature and ensure stable quality of a drug solution.

Abstract: The present disclosure provides a method for preparing a microcapsule and a microcapsule prepared thereby capable of selective release of oils and preventing volatilization of oils while maintaining long-term performance by improving storage stability of the oil contained in the capsule.

Abstract: Cosmetic compositions capable of forming a multilayer structure after application to a keratinous material containing a combination of silicone resins are provided, as well as methods of applying such compositions to a keratinous material.

Abstract: A cosmetic composition in the form of a creamy emulsion having an internal water phase in an oil phase includes at least one polyglyceryl ester, a glutamic acid, or a derivative thereof, at least one cosmetically acceptable glycol or diol, at least one oil, water, and optionally one or more additives. The composition excludes mineral and organic UV filters. The creamy emulsion demonstrates breaking and release of the water phase upon rubbing application of the composition on a substrate. The composition demonstrates stability at temperatures in a range from about 5° C. to about 45° C. for a period of eight weeks and under freeze-thaw conditions that range from about ?20° C. to about 25° C., where the stability is evidenced by lack of separation of the water and oil phases and/or maintaining rheological characteristics over time in the absence of rubbing on a substrate.

Abstract: Synthetic blood substitutes and methods for making them. A lipid-amphiphile blood-substitute precursor compound having a hydrophobic fatty acid/acyl moiety, a hydrophilic head moiety including a phosphate group, and a pH responsive moiety. The lipid-amphiphile precursor is configured to self-assemble from a solution mixture of phospholipid and cholesterol in the presence of hemoglobin and an allosteric effector into a hybrid-vesicle resulting from the combined self-assembly of both the amphiphilic lipid-oligomer and the lipids into an advanced vesicular structure containing a hemoglobin/allosteric effector payload.

Abstract: A method for treating undesired implanted calcium phosphate tissue filler by administering an effective amount of a pharmaceutically acceptable hyperosmotic composition. The hyperosmotic composition may be hyperosmotic solution, particularly a hyperosmotic aqueous solution. The hyperosmotic composition is administration to an area containing the undesired calcium phosphate tissue filler. Administration of the hyperosmotic composition can reduce, dilute/or redistribute an undesired amount or accumulation of implanted calcium phosphate tissue filler implanted. Methods herein can ameliorate undesired filler that is implanted in an undesired or unintended location, that migrates to an undesired location, that results in an undesired visual result, and/or that results in undesired compression of surrounding tissue, and/or that results in pain, infection, and/or inflammation.

Abstract: A skin-care aqueous formula includes a guar-based or xantham-based compound, glycerin, and sodium hypochlorite.

Abstract: A cosmetic hair care composition comprises a derivative of waxes obtained by the reaction of simultaneous transesterification of a mixture comprising jojoba wax and sunflower wax, in the presence of polyglycerol-3.

Abstract: The present invention relates to a cosmetic cleansing composition comprising at least: a) one or more vegetable oil(s), in an amount of at least 0.3 pbw relative to the total weight of the composition, b) from about 1 pbw to about 40 pbw, relative to the total weight of the composition, of a surfactant system comprising at least one sultaine surfactant, c) at least 0.1 pbw, relative to the total weight of the composition, of a non-ionic thickener which is a polyether endcapped by fatty acid esters, and d) at least 0.1 pbw, relative to the total weight of the composition, of a non-ionic solubilizer which is a mono- or poly-alkyl or alkenyl ester of an alkoxylated fatty acid.

Abstract: The present invention relates to a fermented birch sap and a method for producing it, wherein the fermented birch sap is obtained by fermentation using birch sap as a substrate and Inonotus obliquus as a strain; the method comprises the step of fermentation using birch sap as a substrate and Inonotus obliquus as a strain.

Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of topiramate that is from 50 mg/ml to 100 mg/ml and amounts of polyethylene glycol (“PEG”) 400 and glycerol sufficient to result in a greater than a prior art taught calculated maximum amount of the topiramate being in the solution phase of the formulation, at room temperature.

Abstract: Disclosed are shelf stable water miscible suspension systems for suspending microbes and/or microbe derived metabolites so they are water dispersible and can be combined with a variety of agricultural chemicals in an aqueous solution. The microbes and/or microbe derived metabolites are initially suspended in a plant derived oil and then this oil suspension is converted to a water dispersible suspension using one of the disclosed suspension systems. The microbe and/or microbe derived metabolites in the suspension systems are shelf stable for at least 52 weeks at 25° C.